Pfizer Inc.

NYSE:PFE   3:56:41 PM EDT
37.25
+0.72 (+1.97%)
4:24:46 PM EDT: $37.27 +0.02 (+0.05%)
Products, Regulatory

Pfizer Publishes Analysis From Phase 3 ATTR-ACT And Its Long-Term Extension Study

Published: 11/12/2020 18:57 GMT
Pfizer Inc (PFE) - Analysis From Phase 3 Attr-act and Its Long-term Extension Study Demonstrates Vyndaqel® 80 Mg/vyndamax® 61 Mg Significantly Improved Survival in Patients With Transthyretin Amyloid Cardiomyopathy (attr-cm) Compared to Vyndaqel 20 Mg.
Pfizer Inc - Both Vyndaqel 80 Mg/vyndamax 61 Mg and Vyndaqel 20 Mg Were Associated With Safety Profiles Similar to Placebo.
Pfizer Inc - Both Vyndaqel 80 Mg/vyndamax 61 Mg and Vyndaqel 20 Mg Were Associated With Safety Profiles Similar to Placebo.
Pfizer - Analysis of Phase 3 Attr-act Clinical Trial Combined With Long-term Extension Study Published in European Journal of Heart Failure.